CBD for Alcohol Use Disorders: An Updated Review Highlights Preclinical Promise and Human Nuance
A major review evaluates CBD for alcohol use disorder across recent clinical literature. Emerging findings show that while preclinical models indicated reduced consumption, human trials of CBD isolate remain largely null. Clinicians and patients should…
Nonintoxicating Cannabinoids Eased Arthritis Pain in This Study. There Was No Placebo Group.
A 2026 study in Clinical Therapeutics reported that three oral cannabinoid formulations improved pain and related symptoms in fibromyalgia, rheumatoid arthritis, and osteoarthritis over twelve weeks, with no placebo group. Every placebo-controlled trial…
A Paris Laboratory Found That CBD Blocks HIV in Human Tissue. It Is Not a Prevention Strategy.
New laboratory work on CBD and HIV transmission comes from Institut Cochin in Paris, where cannabidiol inhibited HIV-1 infection of mucosal immune cells through the TRPV1 channel rather than through cannabinoid receptors. The effect held in donated human…
Running CBD and the Ketogenic Diet Together: What a 58-Patient Johns Hopkins Cohort Found
A multicenter Johns Hopkins cohort of 58 patients is the first published account of using CBD and ketogenic diet for epilepsy at the same time, and ketosis held in 87 percent of them. Seizure outcomes resembled what either therapy produces alone, with…
The CBD Drug Interactions That Are Actually Documented, and the Doses at Which They Happen
CBD and prescription drug interactions are usually described without the two details that decide whether a warning applies to you: which drug, and at what cannabidiol dose. The interactions with real human evidence behind them involve clobazam,…
Pre-Seizure Symptoms: What an Aura Is, What a Prodrome Is, and Why the Difference Matters Diagnostically
Pre-seizure symptoms fall into two categories that get confused constantly. The aura, which the 2017 International League Against Epilepsy classification treats as the beginning of a focal aware seizure, carries localizing value, while the prodrome can…
Where Pediatric Cannabinoid Evidence Is Strong, Where It Is Thin, and Where It Does Not Exist At All
Medical cannabis for children has randomized, placebo-controlled evidence in exactly three drug-resistant epilepsy syndromes, using a pharmaceutical cannabidiol preparation under specialist supervision. The largest autism trial reported a null primary…
Blog: What Cannabinoid Safety for Autistic Children Requires
Cannabinoid safety for autistic children requires more precision than broad claims about cannabis and autism. Randomized trials of purified CBD and CBD-dominant formulations have produced mixed results, including negative primary outcomes alongside…
CBD for Pericarditis: What the New JAHA Trial Shows
CBD for recurrent pericarditis produced early pain and inflammation signals in a 27-person Phase II pilot trial. Most participants entering the extension remained recurrence-free while standard medications were tapered, but the study had no placebo group…
CBD for Severe Autism: What a 27-Month Study Found
A new long-term observational study published in Pharmacology Biochemistry and Behavior followed children with severe autism spectrum disorder on purified CBD for an average of 27.6 months. Improvements seen at three months were maintained, and 40% of…